



MRI assessment of cerebral oxygen extraction fraction in the medial temporal lobe

Dengrong Jiang¹, Peiying Liu¹, Zixuan Lin¹, Kaisha Hazel¹, George Pottanat¹, Emma Lucke², Abhay Moghekar³, Jay J. Pillai^{1,4}, Hanzhang Lu^{1,5,6}

¹Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA

²Department of Biology, Johns Hopkins University School of Arts & Sciences, Baltimore, Maryland, USA

³Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁴Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁵Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁶F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research Institute, Baltimore, MD, USA

1

The 10th ISNVD Annual Meeting on
Vascular Contributions to Healthy Aging and Dementia

Declaration of Financial Interests or Relationships

Speaker Name: Dengrong Jiang


I have no financial interests or relationships to disclose with regard to the subject matter of this presentation.

2

Background

- Medial temporal lobe (MTL) is crucial for memory formation
- MTL is a key area implicated in many diseases:
 - Alzheimer's disease (AD)¹
 - Epilepsy²
 - Schizophrenia³
- Functional biomarkers, e.g., **oxygen extraction fraction (OEF)** may be more sensitive at early stages


MTL atrophy is a biomarker for AD



Jack et al. Neurology 2016;87:539–547

[1] Berron et al. Brain 2020;143:1233-1248 [2] Bonilha et al. Arch Neurol. 2004;61:1379-1384
[3] Mathew et al. JAMA Psychiatry. 2014;71:769-777


3




4

Measure OEF in medial temporal lobe

Arterial-suppressed accelerated T₂-relaxation-under-phase-contrast (AS-aTRUPC)




Tubbs et al. J Neurosurg
2007;106:900-902




5

Scan procedure

TOF Sagittal MIP




TOF Coronal MIP



6

AS-aTRUPC to measure MTL-OEF


Phase reference — Velocity-encoded = Vessel image



$$\text{OEF} = \frac{Y_a - Y_v}{Y_a} \times 100\%$$

$Y_a \rightarrow 98\% \text{ (assumed)}$

Total scan time = 4.8min





7

AS-aTRUPC to measure MTL-OEF

- Study 1: MTL-OEF in young healthy adults
- Study 2: Caffeine challenge
- Study 3: Aging effect

8



Study 1: MTL-OEF in young healthy adults



7M 9F, 29 ± 8 years old

9

Study 1: MTL-OEF in young healthy adults



7M 9F, 29 ± 8 years old

10

Study 2: Caffeine challenge

4M 6F, age 26 ± 4

Baseline: TRUST



Baseline: AS-aTRUPC

Take 200mg caffeine tablet

TRUST

AS-aTRUPC




×8



11

Study 3: Aging effect


Cohort: 7 older adults (4F, age 66 ± 12) + 16 younger adults (9F, age 29 ± 8)
Age range: 19 – 81 years old



12

MTL-OEF in Alzheimer's disease


Control, age 66, male



MTL-OEF = 33.8%

PiB cDVR = 1.08

MCI, age 73, female



MTL-OEF = 28.3%

PiB cDVR = 2.09

MCI: mild cognitive impairment

PiB: [¹¹C]-Pittsburgh compound B tracer

cDVR: mean cortical distribution volume ratio

13

Summary

- We developed a non-invasive technique: AS-aTRUPC to measure MTL-OEF in less than 5min
- MTL-OEF is lower than cortical OEF in healthy adults
- Caffeine challenge study demonstrated the sensitivity of our technique in detecting OEF changes
- MTL-OEF increased with age
- Future work: clinical applications, e.g., Alzheimer's disease

14

Acknowledgement

Johns Hopkins University

Hanzhang Lu, Ph.D.

Peiying Liu, Ph.D.

Jay J. Pillai, M.D.

Abhay Moghekar, M.D.

Sevil Yasar, M.D. Ph.D.

Paul Rosenberg, M.D.

Marilyn Albert, Ph.D.

Zixuan Lin, Ph.D.

George Pottanat, M.S.

Kaisha Hazel, M.S.

Gwenn Smith, M.D.

Grant sponsors

R01 AG064792

RF1 AG071515

R01 NS106711

R01 NS106702

R21 AG079098

UF1 NS100588

P41 EB031771

RF1 NS110041



JOHNS HOPKINS
MEDICINE